Does Rallies show 13F holders for PAHC?

Yes. Rallies tracks hedge fund and 13F ownership data for PAHC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PAHC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PAHC. It does not provide personalized investment advice.

PAHC (Phibro Animal Health Corporation Class A) Stock Analysis - Hedge Fund Holdings

Phibro Animal Health Corporation Class A (PAHC) is a publicly traded Healthcare sector company. As of May 21, 2026, PAHC trades at $33.75 with a market cap of $1.39B and a P/E ratio of 14.56. PAHC moved -0.34% today. Year to date, PAHC is -11.88%; over the trailing twelve months it is +40.35%. Its 52-week range spans $16.16 to $60.08. Analyst consensus is neutral with an average price target of $44.00. Rallies surfaces PAHC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PAHC stock?

Hedge funds tracked by Rallies that own PAHC include Mangrove Partners and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phibro Animal Health Corporation Class A.

PAHC Key Metrics

Key financial metrics for PAHC
Metric	Value
Price	$33.75
Market Cap	$1.39B
P/E Ratio	14.56
EPS	$2.34
Dividend Yield	0.12%
52-Week High	$60.08
52-Week Low	$16.16
Volume	2
Avg Volume	0
Revenue (TTM)	$1.50B
Net Income	$95.23M
Gross Margin	32.54%

Top Hedge Funds Holding PAHC

Mangrove Partners holds 16.66K shares of PAHC, changed +0.00% as of Mar 31, 2026.
Polen Capital holds 6.78K shares of PAHC, changed +0.00% as of Mar 31, 2026.

Latest PAHC News

Phibro Animal Health Q2 EPS 26.1% Above Estimates on $373.9M Revenue Beat — Mar 10, 2026
Clover Health Guides to Profitability with $50–$70M EBITDA, 38% Membership Growth — Mar 4, 2026
Phibro Animal Health Q2 EPS Beats by 26.1% with $373.9M Revenue Beat — Mar 4, 2026
Phibro Animal Health Secures #1 Buy Rank, 21.5% Growth in Low-PEG List — Feb 26, 2026
Phibro Animal Health’s Consensus Estimate Rises 7.6% While Shares Gain 24.6% — Feb 20, 2026

Recent PAHC Insider Trades

BENDHEIM JACK sold 1.35K (~$64.25K) on May 7, 2026.
BENDHEIM JACK sold 1.15K (~$55.51K) on May 7, 2026.
BENDHEIM JACK sold 2.03K (~$99.82K) on May 7, 2026.

PAHC Analyst Consensus

1 analysts cover PAHC: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.00.

Common questions about PAHC

Who owns PAHC stock?: Hedge funds tracked by Rallies that own PAHC include Mangrove Partners and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Phibro Animal Health Corporation Class A.
Does Rallies show 13F holders for PAHC?: Yes. Rallies tracks hedge fund and 13F ownership data for PAHC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PAHC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PAHC. It does not provide personalized investment advice.